sarcoma cells

[Communications Biology] The authors discuss promising Matrigel-free methods for the generation and maintenance of organoids that use decellularized ECM, synthetic hydrogels, or gel-forming recombinant proteins.

[Rakovina Therapeutics, Inc.] Rakovina Therapeutics, Inc. announced that the company has been selected to join a three year US $975,000 research program funded by the St. Baldrick’s Foundation Martha’s BEST Grant for All, which is aimed at developing new treatments for Ewing sarcoma, an aggressive bone and soft tissue cancer in children and young adults.

[Cancer Immunology Research] Investigators examined the antitumor effects of EWS/FLI1-rejTs against Ewing sarcoma. The altered amino acid sequence at the break/fusion point of EWS/FLI1, when presented as a neoantigen, evokes an immune response that targets EWS/FLI1+ sarcoma. examined the antitumor effects of EWS/FLI1-rejTs against Ewing sarcoma.

[Journal of Experimental & Clinical Cancer Research] Bioinformatic analysis, quantitative mRNA and protein expression analysis, cell models of sarcoma by ectopic expression ofEMX genes. Researchers measured tumorigenesis and populations enriched on stem cell phenotypes, either in vitro or in vivo.

[Cell Reports] Researchers reported that Ewing sarcoma cells were dependent on the autocrine signaling mediated by NELL2, a secreted glycoprotein that has been characterized as an axon guidance molecule.

[Advanced Science] Speckle-type POZ protein (SPOP) and OTU domain-containing protein 7A (OTUD7A) are identified as the bona fide E3 ligase and deubiquitinase, respectively, that control Ewing sarcoma breakpoint region 1-Friend leukemia integration 1 (EWS–FLI1) protein turnover in Ewing sarcoma.